Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Announce Quarterly Sales of $3.61 Million

Share on StockTwits

Equities research analysts expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to post sales of $3.61 million for the current quarter, Zacks reports. Two analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings, with the highest sales estimate coming in at $5.21 million and the lowest estimate coming in at $2.00 million. GW Pharmaceuticals PLC- posted sales of $2.86 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.2%. The firm is scheduled to announce its next quarterly earnings report on Monday, December 3rd.

On average, analysts expect that GW Pharmaceuticals PLC- will report full-year sales of $12.05 million for the current year, with estimates ranging from $3.60 million to $17.82 million. For the next financial year, analysts expect that the company will post sales of $104.04 million, with estimates ranging from $64.30 million to $134.37 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. The company had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $2.00 million.

A number of research firms have recently issued reports on GWPH. ValuEngine upgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 2nd. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $166.00 target price for the company in a research note on Wednesday, July 25th. BidaskClub cut shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. Bank of America reissued a “buy” rating and issued a $197.00 price target (up previously from $181.00) on shares of GW Pharmaceuticals PLC- in a report on Friday, September 28th. Finally, Morgan Stanley raised their price target on shares of GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the company an “overweight” rating in a report on Friday, September 28th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. GW Pharmaceuticals PLC- currently has an average rating of “Buy” and a consensus price target of $185.00.

Shares of NASDAQ:GWPH traded down $2.31 during trading on Friday, reaching $135.90. The stock had a trading volume of 504,110 shares, compared to its average volume of 452,952. GW Pharmaceuticals PLC- has a 52 week low of $101.32 and a 52 week high of $179.65. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $4.21 billion, a P/E ratio of -19.55 and a beta of 2.61.

Several institutional investors have recently modified their holdings of the stock. Morgan Stanley increased its holdings in shares of GW Pharmaceuticals PLC- by 9.8% in the second quarter. Morgan Stanley now owns 378,776 shares of the biopharmaceutical company’s stock valued at $52,855,000 after purchasing an additional 33,784 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of GW Pharmaceuticals PLC- by 45.1% in the second quarter. Baker BROS. Advisors LP now owns 321,800 shares of the biopharmaceutical company’s stock valued at $44,904,000 after purchasing an additional 100,000 shares in the last quarter. Fred Alger Management Inc. increased its holdings in shares of GW Pharmaceuticals PLC- by 240.7% in the second quarter. Fred Alger Management Inc. now owns 321,688 shares of the biopharmaceutical company’s stock valued at $44,888,000 after purchasing an additional 227,264 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of GW Pharmaceuticals PLC- by 2.5% in the second quarter. Victory Capital Management Inc. now owns 306,510 shares of the biopharmaceutical company’s stock valued at $42,770,000 after purchasing an additional 7,535 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 20.8% in the first quarter. Millennium Management LLC now owns 239,774 shares of the biopharmaceutical company’s stock valued at $27,015,000 after purchasing an additional 41,349 shares in the last quarter. 69.79% of the stock is owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Story: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.